A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 188 participants.

Also called NCT07702890

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 188 participants (planned count) (from the registry)
Sponsor
Gubra A/S (from the registry)
Registry
  • NCT NCT07702890
  • EU CT 2025-524921-42-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07702890. Randomized; double masking; primary purpose treatment. Start 2026-07-27 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
Condition
Obesity
Intervention (Drug)
GUB-UCN2
Intervention (Drug)
Placebo
Lead sponsor
Gubra A/S (class: industry)

Record details

Record id
cardio:ct-nct07702890
Content hash
283721dde31acb7545451d6fa18729b90bd4b460ab61e98d31b1c1f5dd0e4cb3